Abstrak RSS

Total lymphocyte count is a reliable surrogate marker for CD4 cell counts after the first year of antiretroviral therapy: data from an Indonesian cohort study

Total lymphocyte count is a reliable surrogate marker for CD4 cell counts after the first year of antiretroviral therapy: data from an Indonesian cohort study
Marrigje A. de Jong, Rudi Wisaksana, Hinta Meijerink, Agnes Indrati, Andre J. A. M. van de Ven, Bachti Alisjahbana, Reinout van Crevel
Universitas Padjadjaran, Tropical Medicine and International Health volume 17 no 5 pp 581–583 may 2012 , doi:10.1111/j.1365-3156.2012.02961.x
Inggris
Universitas Padjadjaran, Tropical Medicine and International Health volume 17 no 5 pp 581–583 may 2012 , doi:10.1111/j.1365-3156.2012.02961.x

Many studies have evaluated the total lymphocyte count (TLC) as a cheap surrogate marker for CD4 cells in HIV-infected patients not receiving antiretroviral therapy (ART). We assessed whether TLC can replace CD4 cell counts in evaluating the immunological response to ART. In a cohort of patients in Indonesia TLC, if measured after at least 1-year ART, correctly identified patients with <200 CD4 cells, and reliably excluded immunological failure, obviating the need for CD4 cell measurement in 43% of patients.

Download: .Full Papers